Topic: Payment & Reimbursement

  • The “Netflix Model” of Financing Hepatitis C Treatment

    The “Netflix Model” of Financing Hepatitis C Treatment

  • Cardiovascular Drugs Not Price Aligned with Value in US

  • Perspective on National Coverage Analysis of CAR-T Therapies

    Perspective on National Coverage Analysis of CAR-T Therapies

  • Spending On Prescription Drugs In The US: Where Does All The Money Go?

    Spending On Prescription Drugs In The US: Where Does All The Money Go?

  • DPL responds to HHS Blueprint (May 16, 2018)

  • Impact of President Trump’s Proposed 340B Hospital Eligibility Threshold

    Impact of President Trump’s Proposed 340B Hospital Eligibility Threshold

  • Does the 6% in Medicare Part B Drug Reimbursement Affect Prescribing?

    Does the 6% in Medicare Part B Drug Reimbursement Affect Prescribing?

  • Money-Back Guarantees for Expensive Drugs: Wolf’s Clothing but a Sheep Underneath

    Money-Back Guarantees for Expensive Drugs: Wolf’s Clothing but a Sheep Underneath

  • Outcomes-Based Drug Contracts Do Not Move Us Closer to Value

    Outcomes-Based Drug Contracts Do Not Move Us Closer to Value

  • Copay Assistance: The Epipen Example

    Copay Assistance: The Epipen Example